| Catalog No. | Size | Price (USD) |
| 11188-MM06-F-25 | 25 Tests | $103.68 |
| 11188-MM06-F-100 | 100 Tests | $325.84 |
General Information
| Product name | Anti-B7-H3 Antibody (FITC), Mouse Monoclonal |
| Validated applications | FCM (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human B7-H3 |
| Immunogen | Recombinant Human B7-H3 / CD276 protein (Catalog#11188-H08H) |
| Preparation | This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human B7-H3 / CD276 (rh B7-H3 / CD276; Catalog#11188-H08H; Q5ZPR3-1; Met 1-Thr 461) and conjugated with FITC under optimum conditions, the unreacted FITC was removed. |
| Source | Monoclonal Mouse IgG2b Clone #06 |
| Purification | Protein A |
| Formulation | PBS solution containing 0.5% BSA and 0.03%ProClin300 |
| Concentration | 10 μl/Test, 0.1 mg/ml |
| Conjugate | FITC |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for twelve months without detectable loss of activity. Protected from prolonged exposure to light. Do not freeze ! |
Synonyms: Anti-B7-H3 Antibody; Anti-B7H3 Antibody; Anti-B7RP-2 Antibody; Anti-PSEC0249 Antibody; Anti-UNQ309/PRO352 Antibody
Image / Experimental Information
| Image 1 Description | Flow cytometric analysis of anti-B7H3 (CD276) reactivity on PC-3 cells. |
| Image 1 Alt Text | Human B7-H3/CD276 Flow Cytometry (FC) 5433 |
| Image 1 URL | Source image |
Background Information
| Full Name | CD276 molecule |
| Description | B7-H3 is a member of the B7 family of immune regulatory ligands that is thought to attenuate peripheral immune responses through co-inhibition. It plays an important role in adaptive immune responses, and was shown to either promote or inhibit T-cell responses in various experimental systems. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. B7-H3 is a novel protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. Previous studies have correlated its overexpression with poor prognosis and decreased tumor-infiltrating lymphocytes in various carcinomas including uterine endometrioid carcinomas, and mounting evidence supports an immuno-inhibitory role in ovarian cancer prognosis. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity. |
| Research Areas |
|
| Tags |
|
| References |
|
title: Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody.
authors: Xiaomeng Lu; Xinyu Zhan; ...; Dianlong Jia
journal: Molecular Pharmaceutics
date: 2024-12-02
pmid: 39620978
doi: 10.1021/acs.molpharmaceut.4c00891
cited_by_count: 2
techniques: Expressing; Flow Cytometry; Lysis; Staining; Western Blot
bioz_score: 92
-MM06-FITC-PE-APC-PC-3.png){kind=link}